[1] |
Ding X, Xu J, Wang C, et al. Suppression of the SAP18/HDAC1 complex by targeting TRIM56 and Nanog is essential for oncogenic viral FLICE⁃inhibitory protein⁃induced acetylation of p65/RelA, NF⁃κB activation, and promotion of cell invasion and angiogenesis[J]. Cell Death Differ, 2019,26(10):1970⁃1986. doi: 10.1038/s41418⁃018⁃0268⁃3.
|
[2] |
高艳, 王鹏, 康晓静. 卡波西肉瘤治疗研究新进展[J]. 中华皮肤科杂志, 2021,54:e20210303. doi: 10.35541/cjd.20210303.
|
[3] |
陈荣荣, 郭浩, 徐砚通, 等. 中药复方和有效成分对血管新生促进或抑制作用的研究进展[J]. 中草药, 2013,44(23):3413⁃3421. doi:10.7501/j.issn.0253⁃2670.2013.23.027.
|
[4] |
Yang LQ, Li RY, Yang XY, et al. Co⁃administration of Shexiang Baoxin pill and chemotherapy drugs potentiated cancer therapy by vascular⁃promoting strategy[J]. Front Pharmacol, 2019,10:565. doi: 10.3389/fphar.2019.00565.
|
[5] |
Zhang YQ, Xia M, Guo QY, et al. Network pharmacology⁃based approaches capture essence of Chinese herbal medicines[J]. Chin Herbal Med, 2016,8(2):107⁃116.
|
[6] |
Yun W, Dan W, Liu J, et al. Investigation of the mechanism of traditional Chinese medicines in angiogenesis through network pharmacology and data mining[J]. Evid Based Complement Alternat Med, 2021,2021:5539970. doi: 10.1155/2021/5539970.
|
[7] |
许炜茹, 张青. 从肺脾辨治罕见汉族经典型卡波西肉瘤验案一则[J]. 中国医药导报, 2018,15(12):148⁃150.
|
[8] |
Safran M, Solomon I, Shmueli O, et al. GeneCards 2002: towards a complete, object⁃oriented, human gene compendium[J]. Bioinformatics, 2002,18(11):1542⁃1543. doi: 10.1093/bioinformatics/18.11.1542.
|
[9] |
Wishart DS, Feunang YD, Guo AC, et al. DrugBank 5.0: a major update to the DrugBank database for 2018[J]. Nucleic Acids Res, 2018,46(D1):D1074⁃D1082. doi: 10.1093/nar/gkx1037.
|
[10] |
Wang Y, Zhang S, Li F, et al. Therapeutic target database 2020: enriched resource for facilitating research and early development of targeted therapeutics[J]. Nucleic Acids Res, 2020,48(D1):D1031⁃D1041. doi: 10.1093/nar/gkz981.
|
[11] |
Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist⁃oriented resource for the analysis of systems⁃level datasets[J]. Nat Commun, 2019,10(1):1523. doi: 10.1038/s41467⁃019⁃09234⁃6.
|
[12] |
Sajadimajd S, Bahramsoltani R, Iranpanah A, et al. Advances on natural polyphenols as anticancer agents for skin cancer[J]. Pharmacol Res, 2020,151:104584. doi: 10.1016/j.phrs.2019.104 584.
|
[13] |
Dyson OF, Walker LR, Whitehouse A, et al. Resveratrol inhibits KSHV reactivation by lowering the levels of cellular EGR⁃1[J]. PLoS One, 2012,7(3):e33364. doi: 10.1371/journal.pone.0033364.
|
[14] |
Uvez A, Aydinlik S, Esener O, et al. Synergistic interactions between resveratrol and doxorubicin inhibit angiogenesis both in vitro and in vivo[J]. Pol J Vet Sci, 2020,23(4):571⁃580. doi: 10.24425/pjvs.2020.135803.
|
[15] |
李聪, 胡强, 张燕翔, 等.槲皮素的药理学活性研究进展[J].湖北中医杂志, 2018,40(6):63⁃64,封3-封4.
|
[16] |
张丹丹, 方建国, 陈娟娟, 等. 连翘及其主要有效成分槲皮素体外抗人巨细胞病毒的实验研究[J]. 中国中药杂志, 2010,35(8):1055⁃1059. doi: 10.4268/cjcmm20100826.
|
[17] |
Matsubara K, Ishihara K, Mizushina Y, et al. Anti⁃angiogenic activity of quercetin and its derivatives[J]. Lett Drug Des Discov, 2004,1(4):329⁃333. doi: 10.2174/1570180043398533.
|
[18] |
Granato M, Gilardini Montani MS, Angiolillo C, et al. Cytotoxic drugs activate KSHV lytic cycle in latently infected PEL cells by inducing a moderate ROS increase controlled by HSF1, NRF2 and p62/SQSTM1[J]. Viruses, 2018,11(1). doi: 10.3390/v11010008.
|
[19] |
Sharma⁃Walia N, Paul AG, Bottero V, et al. Kaposi′s sarcoma associated herpes virus (KSHV) induced COX⁃2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion[J]. PLoS Pathog, 2010,6(2):e1000777. doi: 10.1371/journal.ppat.1000777.
|
[20] |
Haas DA, Bala K, Büsche G, et al. The inflammatory kinase MAP4K4 promotes reactivation of Kaposi′s sarcoma herpesvirus and enhances the invasiveness of infected endothelial cells[J]. PLoS Pathog, 2013,9(11):e1003737. doi: 10.1371/journal.ppat. 1003737.
|
[21] |
Sharma⁃Walia N, Paul AG, Bottero V, et al. Kaposi′s sarcoma associated herpes virus (KSHV) induced COX⁃2: a key factor in latency, inflammation, angiogenesis, cell survival and invasion[J]. PLoS Pathog, 2010,6(2):e1000777. doi: 10.1371/journal.ppat.1000777.
|
[22] |
Gallo O, Franchi A, Magnelli L, et al. Cyclooxygenase⁃2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis[J]. Neoplasia, 2001,3(1):53⁃61. doi: 10.1038/sj.neo.7900127.
|
[23] |
Li S, Jiang M, Wang L, et al. Combined chemotherapy with cyclooxygenase⁃2 (COX⁃2) inhibitors in treating human cancers: Recent advancement[J]. Biomed Pharmacother, 2020,129:110389. doi: 10.1016/j.biopha.2020.110389.
|
[24] |
Ramaswami R, Uldrick TS, Polizzotto MN, et al. A pilot study of liposomal doxorubicin combined with bevacizumab followed by bevacizumab monotherapy in patients with advanced kaposi sarcoma[J]. Clin Cancer Res, 2019,25(14):4238⁃4247. doi: 10. 1158/1078⁃0432.CCR⁃18⁃3528.
|
[25] |
Medina MV, D Agostino A, Ma Q, et al. KSHV G⁃protein coupled receptor vGPCR oncogenic signaling upregulation of Cyclooxygenase⁃2 expression mediates angiogenesis and tumorigenesis in Kaposi′s sarcoma[J]. PLoS Pathog, 2020,16(10):e1009006. doi: 10.1371/journal.ppat.1009006.
|
[26] |
Bhatt AP, Damania B. AKTivation of PI3K/AKT/mTOR signaling pathway by KSHV[J]. Front Immunol, 2012,3:401. doi: 10.3389/fimmu.2012.00401.
|
[27] |
Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis[J]. Adv Cancer Res, 2009,102:19⁃65. doi: 10.1016/ S0065⁃230X(09)02002⁃8.
|
[28] |
Alomari N, Totonchy J. Cytokine⁃targeted therapeutcs for KSHV⁃associated disease[J]. Viruses, 2020,12(10):1097. doi: 10.3390/ v12101097.
|
[29] |
周昊言, 孙若岚, 季千惠, 等. 基于网络药理-分子对接解析川芎-赤芍药对干预脑缺血的作用机制[J]. 中国中药杂志, 2021,46(12):3007⁃3015. doi: 10.19540/j.cnki.cjcmm.20210225. 401.
|